STRATA Skin Sciences to Participate in the H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a leader in medical technology for dermatology, announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 11 to January 14, 2021. The presentation will be available on demand starting January 11 on the Company’s website. STRATA develops innovative products like the XTRAC excimer laser, targeting dermatologic conditions such as psoriasis and vitiligo, impacting over 35 million Americans. The Company's unique DTC advertising model has expanded its network to over 813 clinics and over 2,000 devices globally, enhancing patient access to treatment.

HORSHAM, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the Company will participate in the upcoming H.C. Wainwright BioConnect Virtual Conference.

Dates: Monday, January 11 to Thursday, January 14, 2021
Format: Presentation available on demand beginning January 11, 2021
A link to the presentation will be available on the “Investors” section of the Company’s website at www.strataskinsciences.com.

About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.

The Company’s proprietary XTRAC® excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma diseases which impact over 35 million patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatment to vitiligo patients.

STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.

The XTRAC business has used this proven DTC model to grow its domestic dermatology partner network to over 813 clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC patients an introduction to physicians prescribing a reimbursable solution, using XTRAC, within a 10-mile radius of their house. The Company is a leader in dermatology in-clinic business generation for its partners.

Investor Contacts:

Leigh Salvo

(415) 937-5404

ir@strataskin.com

FAQ

What are the dates for the H.C. Wainwright BioConnect Virtual Conference involving SSKN?

The conference will take place from January 11 to January 14, 2021.

How can I access STRATA's presentation at the conference?

The presentation will be available on demand starting January 11, 2021, on STRATA's website.

What products does STRATA Skin Sciences focus on?

STRATA specializes in products for treating dermatologic conditions, including the XTRAC excimer laser and VTRAC lamp systems.

How many clinics has STRATA partnered with for its XTRAC business?

STRATA has partnered with over 813 dermatology clinics for its XTRAC services.

What is the significance of the XTRAC technology?

The XTRAC excimer laser provides targeted UVB light therapy for skin conditions impacting over 35 million patients in the U.S.